CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
cyclophosphamide +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002466
NCT00002466Phase 2Completed
CompareCT.gov

Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 26, 2004·Updated Jun 20, 2013

In Brief

A Phase 2 clinical trial evaluating cyclophosphamide, doxorubicin hydrochloride, and 5 other interventions for Kidney Cancer and Sarcoma. Completed, across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating patients with peripheral neuroectodermal tumors, Ewing's sarcoma, Wilms' tumor, or bone cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer, Sarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 26, 2004
Enrollment StartMay 1, 1990
Primary CompletionMay 1, 2005
TodayJul 2, 2026
Enrollment to primary: 15 yearsPosted 22.2 years ago

Interventions

cyclophosphamidedrug

doxorubicin hydrochloridedrug

etoposidedrug

ifosfamidedrug

vincristine sulfatedrug

conventional surgeryprocedure

radiation therapyradiation